ArticleNature nanotechnology2026
Chemical efflux imaging using an annular nanosensor array for in situ bladder cancer detection.
Article in Nature nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanosensor-coated catheters for bladder cancer detection.Nature nanotechnology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detection of analytes in extracted biofluids, such as urine for bladder cancer biomarkers, is challenging owing to sample dilution and instability outside the human body. Here we demonstrate an annular nanosensor array grafted onto a standard biomedical catheter, which enables three-dimensional chemical efflux imaging from within a tissue compartment or luminal space. This platform integrates near-infrared fluorescent single-walled carbon nanotubes with the catheter, leveraging a ball-lens scanning optical device for chemical signal mapping. We develop nanosensors based on a phospholipid copolymer that selectively detect nuclear matrix protein (NMP-22), a biomarker for bladder cancer. The results show differential sensor responses between apoptosis in six bladder cancer cell lines and healthy fibroblast cells. Nanosensor-functionalized catheters track gemcitabine-stimulated cell death and monitor protein efflux in vitro. We demonstrate spatial imaging of incident chemical flux using this platform, achieving localization of biomarker sources in complex tissues and organs with 182-fold signal enhancement compared with extracted biofluid sampling. As an application, the catheter equipped with a rotating ball lens chemically images porcine bladders, detecting biomarker efflux up to 2 cm away, highlighting its potential as a point-of-care diagnostic tool.
Indexed as
Identifiers
42204302What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.